Evaluation of Medication Exposure on Exacerbation of Disease in Patients With Myasthenia Gravis.

Nick Petrucelli Megan E BarraJennifer L Koehl

Published in: The Neurohospitalist (2023)

Of the medications reported to potentially worsen MG, intravenous labetalol and intravenous magnesium were the 2 agents associated with myasthenic exacerbations with a higher incidence in patients harboring additional risk factors.

Keyphrases

risk factors
chronic obstructive pulmonary disease
myasthenia gravis
end stage renal disease
high dose
newly diagnosed
ejection fraction
chronic kidney disease
healthcare
cystic fibrosis
prognostic factors
low dose
intensive care unit
patient reported outcomes
patient reported